. 2020 Sep 22;2020:9456350. doi: 10.1155/2020/9456350

Table 1.

The results of peripheral blood routine between control group and treatment groups ( $\bar{x} + s$ , n = 8).

Group	WBC (10⁹/L)	RBC (10¹²/L)	HGB (g/L)	NE (%)	LY (%)	MO (%)	HCT (%)	PLT (10⁹/L)
Control	5.08 ± 0.82	8.04 ± 0.73	144.88 ± 5.33	15.05 ± 1.51	71.15 ± 3.34	17.49 ± 2.23	39.35 ± 2.04	366.00 ± 19.21
Model	9.11 ± 1.18^##	6.31 ± 0.32^##	128.88 ± 6.31^##	30.36 ± 2.30^##	55.23 ± 4.38^##	24.15 ± 2.19^##	28.91 ± 2.18^##	520.38 ± 49.41^##
AJ	5.26 ± 0.84^∗∗	7.58 ± 0.47^∗∗	141.13 ± 5.08^∗∗	28.46 ± 2.69	64.91 ± 3.24^∗∗	18.61 ± 1.32^∗∗	38.01 ± 2.13^∗∗	447.25 ± 28.97^∗∗
XSHG	5.73 ± 0.96^∗∗	7.66 ± 0.32^∗∗	140.75 ± 5.18^∗∗	28.89 ± 1.54	66.45 ± 3.06^∗∗	19.49 ± 1.11^∗∗	37.03 ± 2.24^∗∗	481.75 ± 40.75
DY	6.49 ± 0.82^∗∗	6.53 ± 0.37^∆∆	130.50 ± 4.24^∆∆	27.68 ± 3.21	57.40 ± 3.87^∆∆	21.21 ± 2.36^∗	33.05 ± 3.23^∗∗^∆∆	542.13 ± 47.43^∆∆
DC	6.28 ± 0.58^∗∗	6.81 ± 0.52^∆∆	131.25 ± 5.90^∆∆	28.65 ± 1.97	59.33 ± 2.96^∆∆	21.09 ± 1.72^∗	34.56 ± 1.54^∗∗	529.88 ± 22.96^∆
DT	6.58 ± 1.19^∗∗	7.40 ± 0.54^∗∗	139.13 ± 3.80^∗∗	26.40 ± 3.06^∗∗	61.06 ± 3.17^∗∗^∆	20.66 ± 2.16^∗∗	37.74 ± 1.95^∗∗	469.63 ± 28.39^∗
DH	7.08 ± 0.60^∗∗^∆	7.20 ± 0.41^∗∗	136.38 ± 3.66^∗	28.84 ± 2.13	60.16 ± 4.08^∗^∆∆	21.18 ± 2.23^∗	36.03 ± 1.87^∗∗	512.75 ± 46.41
DJ	6.44 ± 0.99^∗∗	7.56 ± 0.39^∗∗	143.38 ± 4.75^∗∗	28.76 ± 2.03	62.05 ± 2.87^∗∗^∆	20.74 ± 1.65^∗∗	36.21 ± 2.64^∗∗	487.38 ± 29.18
DZ	6.78 ± 1.04^∗∗	7.46 ± 0.34^∗∗	138.88 ± 5.03^∗∗	30.09 ± 2.46	60.13 ± 2.98^∗^∆∆	20.96 ± 1.52^∗∗	35.61 ± 1.63^∗∗	489.00 ± 27.92

^# P < 0.05 and ^##P < 0.01 versus control group; ^∗P < 0.05 and ^∗∗P < 0.01 versus model group; ^ΔP < 0.05 and ^ΔΔP < 0.01 versus XSHG group. WBC: white blood cell count; RBC: red blood cell count; HGB: hemoglobin; NE: neutrophil ratio; LY: lymphocyte ratio; MO: monocyte ratio; HCT: haematocrit; PLT: platelet count.